Inclusion Criteria:  Before any evaluation, an informed consent form voluntarily signed by the patient must be obtained; 18 -75 years old (at the time of screening visit V1), male or female; MRI-PDFF ≥ 8% ; Liver stiffness value ( LSM ) 7.0-11.0kPa ; Triglyceride ( TG ) ≥1.7mmol/L and ≤5.6 mmol/L; HOMA-IR ≥ 2.5 ; Serum Alanine aminotransferease (ALT) ≥ the upper limit of normal during screening.  Exclusion Criteria:  Type 1 diabetes;  Any of the following for type 2 diabetes:  HbA1c ≥ 8.5% during screening At the time of screening, ≥ 2 oral hypoglycemic drugs combinations Receiving any of the following medications at screening: Thiazolidinediones (TZD) drugs, fibrates, glucagon-like peptide-1 (GLP-1) receptor agonists, insulin Existing other liver diseases or history of liver diseases History of transient ischemic attack or cerebrovascular accident; History of myocardial infarction, or coronary angioplasty or coronary artery bypass surgery, unstable angina, heart failure (New York Heart Association NYHA grade III / IV ), or ECG signs of left ventricular hypertrophy, or serious arrhythmias ； During screening, blood pressure ≥ 160/100 mmHg ; Previous or planned ( during the study period) bariatric surgery; Liver transplantation history or planned liver transplantation; Liver biopsy show liver cirrhosis or clinically diagnosed as cirrhosis; Weight loss of more than 5% in 6 months before screening; History of edema of lower limbs or whole body; diagnosed as osteoporosis or any other known bone disease; Donated blood or lost blood >400 ml within 8 weeks before the first medication; With MRI scan contraindications; In the past 5 years, there was a history of malignant tumors of any organ system; Human immunodeficiency virus ( HIV ) test is positive; Heavy drinking of alcohol for more than 3 months in a year; Heavy smoking >30 per day within 1 year; History of drug abuse in 12 months; Drugs cumulatively for more than 1 month in the previous 3 months before screening, such as obeticholic acid ( OCA ), berberine; Drugs that may cause liver damage for more than 2 weeks within 1 year before screening; Patients received the following medications unless they have received a stable dose for at least 1 month before screening :Beta-blockers, thiazide diuretics, statins, niacin, ezetimibe, thyroid hormone; The calculated eGFR < 60 mL/(min*1.73m^2 ); There is clinical evidence of liver decompensation or severe liver damage; Low density lipoprotein cholesterol (LDL-C) ≥ 3.4 mmol/L during screening ; Platelet < 100×10^9 /L ; Patient participating in other clinical trials of drugs or medical devices within 3 months prior to screening ; Pregnant or breastfeeding women.